<code id='5A132D8B30'></code><style id='5A132D8B30'></style>
    • <acronym id='5A132D8B30'></acronym>
      <center id='5A132D8B30'><center id='5A132D8B30'><tfoot id='5A132D8B30'></tfoot></center><abbr id='5A132D8B30'><dir id='5A132D8B30'><tfoot id='5A132D8B30'></tfoot><noframes id='5A132D8B30'>

    • <optgroup id='5A132D8B30'><strike id='5A132D8B30'><sup id='5A132D8B30'></sup></strike><code id='5A132D8B30'></code></optgroup>
        1. <b id='5A132D8B30'><label id='5A132D8B30'><select id='5A132D8B30'><dt id='5A132D8B30'><span id='5A132D8B30'></span></dt></select></label></b><u id='5A132D8B30'></u>
          <i id='5A132D8B30'><strike id='5A132D8B30'><tt id='5A132D8B30'><pre id='5A132D8B30'></pre></tt></strike></i>

          Home / Wikipedia / knowledge

          knowledge


          knowledge

          author:Wikipedia    Page View:894

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In